Torch

Dr David Allsup

Senior Lecturer in Haematology and Honorary Consultant

Faculty and Department

  • Faculty of Health Sciences
  • Hull York Medical School

Qualifications

  • BSc (University of Leicester)
  • PhD (University of Liverpool)
  • BSc (University of Leicester)

Summary

Dr David Allsup is a Senior Lecturer in Haematology with an Honorary NHS appointment with Hull and East Yorkshire Hospitals NHS Trust, based in the Queens Centre for Oncology and Haematology at Castle Hill Hospital. He is the local haemophilia director and has additional clinical interests in inherited and acquired platelet disorders. He is also the local lead for chronic lymphocytic leukaemia (CLL), in which he has a longstanding research interest.

Dr Allsup is a keen educator and supporter of the next generation of scientists and clinicians. His teaching roles include:-

Academic lead for the Hull York Medical School Phase II Scholarship and Special Interests Programme.

Undergraduate medical student teaching in phase II.

Haematology postgraduate teaching.

Educational and clinical supervisor to medical and haematology trainees.

Recent outputs

View more outputs

Journal Article

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Chatzikonstantinou, T., Kapetanakis, A., Scarfò, L., Karakatsoulis, G., Allsup, D., Cabrero, A. A., …Ghia, P. (in press). COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01450-8

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Lin, W. Y., Fordham, S. E., Hungate, E., Sunter, N. J., Elstob, C., Xu, Y., …Allan, J. M. (2021). Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature communications, 12(1), https://doi.org/10.1038/s41467-021-26551-x

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

Pepper, A. G., Zucchetto, A., Norris, K., Tissino, E., Polesel, J., Soe, Z., …Pepper, C. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01322-1

COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study

Allsup, D., Howard, D., Emmerson, J., Hockaday, A., Rawstron, A., Oughton, J. B., …Hillmen, P. (in press). COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British journal of haematology, https://doi.org/10.1111/bjh.17526

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia

Molica, S., Allsup, D., Gianfelici, V., Levato, L., Aiello, V., Bailey, J., & Polliack, A. (in press). Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, https://doi.org/10.1080/13543784.2021.1924669

Research interests

His research interests include:-

Platelet disorders.

The biology of chronic lymphocytic leukaemia.

Novel therapeutic approaches for haematological malignancies.

Clinical trials.

Patient pathways.

Postgraduate supervision

Inherited and acquired platelet disorders.

Chronic lymphocytic leukaemia.

Novel treatments for leukaemia.

Clinical trials.

Patient experience of cancer.

Clinical role

Honorary Consultant

2018 - 2019

Honorary Consultant

Committee/Steering group role

Member of Trial Management Group for LIPS

2018 - 2019

Co-investigator, and member of trial management group, of a registry study of acute leukaemia and pregnancy.

Member of Trial Management Group FLAIR clinical trial

2013 - 2021

Member of Trial Management Group FLAIR clinical trial

NCRI CLL clinical studies subgroup member

2010 - 2019

NCRI CLL clinical studies subgroup member

Conference presentation

Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP affect outcome? Data from the UK ITP registry

2020 - 2020

Co-author on above presentation at BSH 2020

Btk inhibitors Ibrutinib and Acalabrutinib impair Fc?RIIA-mediated responses of healthy donor platelets and Chronic Lymphocytic Leukaemia platelets to bacteria.

2020 - 2020

Co-author on above poster presentation at BSH 2020.

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

2020 - 2020

Poster presentation American Society for Haematology Andrea GS Pepper, PhD1*, Antonella Zucchetto, PhD2*, Kevin Norris, PhD3*, Erika Tissino, PhD4*, Jerry Polesel5*, Zarni Soe6*, David Allsup7*, Anna Hockaday8*, Pei Loo Ow9*, Peter Hillmen, MBChB, PhD10*, Andrew Rawstron, PhD11*, Daniel Catovsky, MD, FRCP12, Riccardo Bomben, PhD2*, Duncan M Baird, PhD13*, Christopher Fegan14*, Valter Gattei, MD15 and Chris Pepper, BSc, PhD16

Bruton's Tyrosine Kinase Inhibitors Impair Fc?riia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria

2020 - 2020

1748 Bruton's Tyrosine Kinase Inhibitors Impair Fc?riia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria Program: Oral and Poster Abstracts Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II Hematology Disease Topics & Pathways: Leukemia, Diseases, CLL, Therapies, Biological Processes, Lymphoid Malignancies, Clinically relevant, immune mechanism, pathways Sunday, December 6, 2020, 7:00 AM-3:30 PM Leigh Naylor-Adamson1*, Zoe Booth2*, Simon Hart3*, Russell Patmore4, Sujoy Khan5*, David Allsup6* and Monica Arman6* 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Owston Ferry, ENG, United Kingdom 2Centre for Atherothrombosis and Metabolic Disease, University of Hull, Hull, ENG, United Kingdom 3Respiratory Research Group, Hull York Medical School, Hull, ENG, United Kingdom 4Department of Haematology, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom 5Department of Immunology & Allergy, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom 6Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom

Btk Inhibitor Ibrutinib Impairs Fc?RIIa-Mediated Responses of Platelets from Healthy Donors and Chronic Lymphocytic Leukaemia Patients to Bacteria

2020 - 2020

Authors: Leigh Naylor-Adamson1, Zoe Booth1, Simon P. Hart3, David J Allsup1,4, and Mònica Arman1 Affiliations: 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull; 2Respiratory Research Group, Hull York Medical School, University of Hull; 3Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust. Poster British Society Haematology Meeting 2020

Multicenter Genome Wide Association Study Identifies Constitutional Risk Alleles for Progressive Chronic Lymphocytic Leukemia

2019 - 2019

David Allsup, Wei-Yu Lin, Sarah Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Timothy Barrow, Tryfonia Mainou-Fowler, Rachel Piddock, Helen Marr, Jonathan Wallis, Scott Marshall, Andrew Pettitt, Christopher Pepper, Christopher Fegan, Francesco Forconi, Martin JS Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe David Oscier, Richard S. Houlston, James Bailey, Syed Rais, Alison Bentley, Lynn Cawkwell, Peter Hillmen, Guy Pratt , James Allan. Conference presentation, American Society for Haematology, Orlando, December 2019.

External examiner role

External Phd examiner.

2004 - 2019

Dr Allsup has acted as external examiner in six PhD vivas.

Membership/Fellowship of professional body

Fellow Higher Education Academy

2019

UKHCDO

2005 - 2019

Member of United Kingdom Haemophilia Centre Directors Organisation.

FRCPath

2004 - 2019

Fellow Royal College of Pathologist

BSH

2000 - 2019

Member of British Society for Hematology

MRCP

1996 - 1996

MRCP